Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05113979 · ClinicalTrials.gov registry record

Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery

A clinical trial of Refractive Errors, sponsored by OnPoint Vision.

Completed
Registry status
10
Enrollment target
1
Study location

NCT05113979 is a study of Refractive Errors that has completed, run by OnPoint Vision. The registered enrollment target is 10 participants, below the 106-participant average among 14 other Refractive Errors trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05113979, a study of Refractive Errors, has completed, sponsored by OnPoint Vision.

COMPLETED
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

To determine if the intraocular pseudophakic contact lens (IOPCL), referred to as the AccuraSee, corrects residual refractive errors after cataract surgery using a plus powered lens in subjects with ocular pathology previously implanted with a Bausch and Lomb LI61AO or LI61SE monofocal posterior chamber intraocular lens (PCIOL) and to confirm its positional stability and adherence relative to the PCIOL.

Conditions Studied

Interventions

  • DEVICE AccuraSee IOPCL with +3.0D add

Study Locations (1)

Minnesota

  • Chu Vision Institute - Bloomington

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-03-09
Est. Completion 2022-09-09

Sponsor

OnPoint Vision

3 total trials

What the Registry Record Tells You About NCT05113979

The ClinicalTrials.gov registry entry for NCT05113979 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 14 other Refractive Errors trials with a reported enrollment target (91% lower). The listed sponsor is OnPoint Vision, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Refractive Errors appearing as the primary indexed condition, and to 1 intervention - of which AccuraSee IOPCL with +3.0D add is the first listed.

NCT05113979 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05113979 about?

NCT05113979 is a clinical study titled "Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery". To determine if the intraocular pseudophakic contact lens (IOPCL), referred to as the AccuraSee, corrects residual refractive errors after cataract surgery using a plus powered lens in subjects with ocular pathology previously implanted with a Bausch and Lomb LI61AO or LI61SE monofocal posterior cha...

What is the current status of trial NCT05113979?

This trial is currently completed. The enrollment target is 10 participants. The study started on 2020-03-09. Estimated completion is 2022-09-09.

What conditions does trial NCT05113979 study?

This clinical trial studies the following conditions: Refractive Errors.

What interventions are being tested in trial NCT05113979?

The interventions under investigation include: AccuraSee IOPCL with +3.0D add (DEVICE).

Who is sponsoring clinical trial NCT05113979?

This trial is sponsored by OnPoint Vision, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05113979 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Refractive Errors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.